

B9

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081698 A2(51) International Patent Classification⁷: C12N 15/31, C07K 14/245, C12P 13/08 // (C12P 13/08, C12R 1:19)(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/EP02/02420

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 6 March 2002 (06.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
101 16 518.8 3 April 2001 (03.04.2001) DE

(71) Applicant: DEGUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).

(72) Inventors: RIEPING, Mechthild; Mönkebergstrasse 1, 33619 Bielefeld (DE). HERMANN, Thomas; Zirkonstrasse 8, 33739 Bielefeld (DE).

Published:


— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: PROCESS FOR THE PRODUCTION OF L-AMINO ACIDS USING STRAINS OF THE FAMILY ENTEROBACTERIACEAE THAT CONTAIN AN ATTENUATED fruR GENE



WO 02/081698 A2



(57) Abstract: The invention relates to a process for the production of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of the microorganisms of the family Enterobacteriaceae producing the desired L-amino acid, in which the fruR gene or nucleotide sequences coding therefor are attenuated, in particular are switched off, b) enrichment of the L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid.



- *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**Process for the Production of L-Amino Acids using
Strains of the Family Enterobacteriaceae
that contain an Attenuated fruR Gene**

Field of the Invention

- 5 The present invention relates to a process for the enzymatic production of L-amino acids, in particular L-threonine, using strains of the family Enterobacteriaceae in which the fruR gene is attenuated.

Prior Art

- 10 L-amino acids, in particular L-threonine, are used in human medicine and in the pharmaceutical industry, in the foodstuffs industry, and most especially in animal nutrition.

It is known to produce L-amino acids by fermentation of
15 strains of Enterobacteriaceae, in particular Escherichia coli (E. coli) and Serratia marcescens. On account of their great importance efforts are constantly being made to improve processes for producing the latter. Process improvements may relate to fermentation technology
20 measures, such as for example stirring and provision of oxygen, or the composition of the nutrient media, such as for example the sugar concentration during the fermentation, or the working-up to the product form, for example by ion exchange chromatography, or the intrinsic
25 performance properties of the microorganism itself.

Methods comprising mutagenesis, selection and mutant choice are employed in order to improve the performance properties of these microorganisms. In this way strains are obtained that are resistant to antimetabolites, such as for example
30 the threonine analogue α -amino- β -hydroxyvaleric acid (AHV) or are auxotrophic for regulatorily important metabolites, and that produce L-amino acids such as for example L-

Methods of recombinant DNA technology have also been used for some years in order to improve strains of the family Enterobacteriaceae producing L-amino acids, by amplifying individual amino acid biosynthesis genes and investigating 5 their effect on production.

Object of the Invention

The object of the invention is to provide new measures for the improved enzymatic production of L-amino acids, in particular L-threonine.

10 Summary of the Invention

The invention provides a process for the enzymatic production of L-amino acids, in particular L-threonine, using microorganisms of the family Enterobacteriaceae that in particular already produce L-amino acids and in which 15 the nucleotide sequence coding for the fruR gene is attenuated.

Detailed Description of the Invention

Where L-amino acids or amino acids are mentioned hereinafter, this is understood to mean one or more amino 20 acids including their salts, selected from the group comprising L-asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan and L-25 arginine. L-threonine is particularly preferred.

The term "attenuation" describes in this connection the reduction or switching off of the intracellular activity of one or more enzymes (proteins) in a microorganism that are coded by the corresponding DNA, by using for example a weak 30 promoter or a gene or allele that codes for a corresponding enzyme with a low activity and/or that inactivates the

corresponding enzyme (protein) or gene, and optionally combining these measures.

By means of these attenuation measures the activity or concentration of the corresponding protein is generally
5 reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild type protein, or the activity or concentration of the protein in the initial microorganism.

The process is characterized in that the following steps
10 are carried out:

- a) fermentation of microorganisms of the family Enterobacteriaceae in which the fruR gene is attenuated,
- b) enrichment of the corresponding L-amino acid in the medium or in the cells of the microorganisms of the family Enterobacteriaceae, and
15
- c) isolation of the desired L-amino acid, in which optionally constituents of the fermentation broth and/or the biomass in its entirety or parts thereof remain in the product.
20

The microorganisms that are the subject of the present invention can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch, optionally cellulose or from glycerol and ethanol. The
25 microorganisms are members of the family Enterobacteriaceae selected from the genera Escherichia, Erwinia, Providencia and Serratia. The genera Escherichia and Serratia are preferred. In the case of the genus Escherichia the species Escherichia coli may in particular be mentioned,
30 and in the case of the genus Serratia the species Serratia marcescens may in particular be mentioned.

Suitable strains of the genus *Escherichia*, in particular those of the species *Escherichia coli*, that produce in particular L-threonine, include for example:

- 5 *Escherichia coli* TF427
- Escherichia coli* H4578
- Escherichia coli* KY10935
- Escherichia coli* VNIIgenetika MG442
- Escherichia coli* VNIIgenetika M1
- Escherichia coli* VNIIgenetika 472T23
- 10 *Escherichia coli* BKIIM B-3996
- Escherichia coli* kat 13
- Escherichia coli* KCCM-10132

Suitable strains of the genus *Serratia*, in particular of the species *Serratia marcescens*, that produce L-threonine
15 include for example:

- Serratia marcescens* HNr21
- Serratia marcescens* TLrl56
- Serratia marcescens* T2000

Strains of the family of Enterobacteriaceae producing L-threonine preferably have, *inter alia*, one or more of the genetic or phenotype features selected from the following group: resistance to α -amino- β -hydroxyvaleric acid, resistance to thialysine, resistance to ethionine, resistance to α -methylserine, resistance to diaminosuccinic acid, resistance to α -aminobutyric acid, resistance to borreliadin, resistance to rifampicin, resistance to valine analogues such as for example valine hydroxamate, resistance to purine analogues such as for example 6-dimethylaminopurine, need for L-methionine, optionally 25 partial and compensatable need for L-isoleucine, need for meso-diaminopimelic acid, auxotrophy with regard to threonine-containing dipeptides, resistance to L-threonine, resistance to L-homoserine, resistance to L-lysine, resistance to L-methionine, resistance to L-glutamic acid,
30

- resistance to L-aspartate, resistance to L-leucine,
resistance to L-phenylalanine, resistance to L-serine,
resistance to L-cysteine, resistance to L-valine,
sensitivity to fluoropyruvate, defective threonine
5 dehydrogenase, optionally ability to utilise sucrose,
enhancement of the threonine operon, enhancement of
homoserine dehydrogenase, I-aspartate kinase I, preferably
of the feedback-resistant form, enhancement of homoserine
kinase, enhancement of threonine synthase, enhancement of
10 aspartate kinase, optionally of the feedback-resistant
form, enhancement of aspartate semialdehyde dehydrogenase,
enhancement of phosphoenol pyruvate carboxylase, optionally
of the feedback-resistant form, enhancement of phosphoenol
pyruvate synthase, enhancement of transhydrogenase,
15 enhancement of the RhtB gene product, enhancement of the
RhtC gene product, enhancement of the YfiK gene product,
enhancement of a pyruvate carboxylase, and attenuation of
acetic acid formation.

- It has now been found that microorganisms of the family
20 Enterobacteriaceae after attenuation, in particular after
switching off the fruR gene, produce L-amino acids, in
particular L-threonine, in an improved way.

- The nucleotide sequences of the Escherichia coli genes
belong to the prior art and may also be obtained from the
25 genome sequence of Escherichia coli published by Blattner
et al. (Science 277, 1453 - 1462 (1997)).

The fruR gene is described *inter alia* by the following
data:

- Designation: Fructose repressor
30 EC-No.: -
Reference: Jahreis et al., Molecular and General
Genetics 226, 332-336 (1991)
Accession No.: AE000118

Comment: The fruR gene is also designated in the prior art as cra gene.

Apart from the described fruR gene, alleles of the gene may be used that result from the degeneracy of the genetic code
5 or from functionally neutral sense mutations, the activity of the protein not being substantially altered.

In order to achieve an attenuation of the expression of the gene or the catalytic properties of the enzyme proteins may for example be reduced or switched off. Optionally both
10 measures may be combined.

The gene expression may be reduced by suitable culture conditions, by genetic alteration (mutation) of the signal structures of the gene expression, or also by antisense-RNA techniques. Signal structures of the gene expression are
15 for example repressor genes, activator genes, operators, promoters, attenuators, ribosome-binding sites, the start codon and terminators. The person skilled in the art may find relevant information in, inter alia, articles by Jensen and Hammer (Biotechnology and Bioengineering 58:
20 191-195 (1998)), by Carrier and Keasling (Biotechnology Progress 15, 58-64 (1999)), Franch and Gerdes (Current Opinion in Microbiology 3, 159-164 (2000)) and in known textbooks of genetics and molecular biology, such as for example the textbook by Knippers ("Molekulare Genetik", 6th
25 Edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or that by Winnacker ("Gene und Klone", VCH Verlagsgesellschaft, Weinheim, Germany, 1990).

Mutations that lead to a change or reduction of the catalytic properties of enzyme proteins are known from the
30 prior art. As examples there may be mentioned the works by Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Yano et al. (Proceedings of the National Academy of Sciences, USA 95, 5511-5515 (1998)), Wente and Schachmann (Journal of Biological Chemistry 266, 20833-

20839 (1991)). Descriptive overviews may be obtained from known textbooks on genetics and molecular biology, such as for example that by Hagemann ("Allgemeine Genetik", Gustav Fischer Verlag, Stuttgart, 1986).

- 5 Suitable mutations include transitions, transversions, insertions and deletions. Depending on the action of the amino acid exchange on the enzyme activity, one speaks of missense mutations or nonsense mutations. Insertions or 10 deletions of at least one base pair in a gene lead to frame shift mutations, which in turn lead to the incorporation of false amino acids or the premature termination of a translation. If as a result of the mutation a stop codon is formed in the coding region, this also leads to a premature termination of the translation. Deletions of 15 several codons typically lead to a complete disruption of the enzyme activity. Details regarding the production of such mutations belong to the prior art and may be obtained from known textbooks on genetics and molecular biology, such as for example the textbook by Knippers ("Molekulare 20 Genetik", 6th Edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), that by Winnacker ("Gene und Klone", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or that by Hagemann ("Allgemeine Genetik", Gustav Fischer Verlag, Stuttgart, 1986).
- 25 Suitable mutations in the genes such as for example deletion mutations may be incorporated by gene and/or allele exchange in suitable strains.

A conventional method is the method of gene exchange by means of a conditionally replicating pSC101 derivate 30 pMAK705 described by Hamilton et al. (Journal of Bacteriology 171, 4617 - 4622 (1989)). Other methods described in the prior art, such as for example that of Martinez-Morales et al. (Journal of Bacteriology 181, 7143- 7148 (1999)) or that of Boyd et al. (Journal of 35 Bacteriology 182, 842-847 (2000)) may likewise be used.

It is also possible to transfer mutations in the respective genes or mutations relating to the expression of the relevant genes, by conjugation or transduction into various strains.

- 5 Furthermore for the production of L-amino acids, in particular L-threonine, using strains of the family Enterobacteriaceae it may be advantageous in addition to the attenuation of the fruR gene also to enhance one or more enzymes of the known threonine biosynthesis pathway or
- 10 enzymes of anaplerotic metabolism or enzymes for the production of reduced nicotinamide-adenine-dinucleotide phosphate.

- The term "enhancement" describes in this connection the raising of the intracellular activity of one or more enzymes or proteins in a microorganism that are coded by the corresponding DNA, by for example increasing the number of copies of the gene or genes, using a strong promoter or a gene that codes for a corresponding enzyme or protein having a high activity, and optionally by combining these measures.

- By means of the aforementioned enhancement measures, in particular overexpression, the activity or concentration of the corresponding protein is in general raised by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, 25 at most up to 1000% or 2000% referred to that of the wild type protein and/or the activity or concentration of the protein in the initial microorganism.

- Thus, one or more of the genes selected from the following group may for example be simultaneously enhanced, in particular overexpressed:

- the thrABC operon coding for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765),

- the pyc gene coding for pyruvate carboxylase (DE-A-19 831 609),
- the pps gene coding for phosphoenol pyruvate synthase (Molecular and General Genetics 231:332 (1992)),
5 • the ppc gene coding for phosphoenol pyruvate carboxylase (Gene 31:279-283 (1984)),
• the genes pntA and pntB coding for transhydrogenase (European Journal of Biochemistry 158:647-653 (1986)),
• the gene rhtB imparting homoserine resistance (EP-A-0
10 994 190),
• the mqo gene coding for malate:quinone oxidoreductase (DE 100 348 33.5),
• the gene rhtC imparting threonine resistance (EP-A-1 013 765), and
15 • the thrE gene of Corynebacterium glutamicum coding for threonine export (DE 100 264 94.8).

The use of endogenous genes is in general preferred. The term "endogenous genes" or "endogenous nucleotide sequences" is understood to mean the genes or nucleotide sequences
20 present in the population of a species.

Furthermore for the production of L-amino acids, in particular L-threonine, it may be advantageous in addition to the attenuation of the fruR gene also to attenuate, in particular to switch off or reduce the expression of one or
25 more of the genes selected from the following group:

- the tdh gene coding for threonine dehydrogenase (Ravnikar and Somerville, Journal of Bacteriology 169, 4716-4721 (1987)),

- the *mdh* gene coding for malate dehydrogenase (E.C. 1.1.1.37) (Vogel et al., Archives in Microbiology 149, 36-42 (1987)),
 - the gene product of the open reading frame (orf) *yjfa* 5 (Accession Number AAC77180 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
 - the gene product of the open reading frame (orf) *ytfP* (Accession Number AAC77179 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
 - 10 • the *pckA* gene coding for the enzyme phosphoenol pyruvate carboxykinase (Medina et al. (Journal of Bacteriology 172, 7151-7156 (1990))),
 - the *poxB* gene coding for pyruvate oxidase (Grabau and Cronan (Nucleic Acids Research 14 (13), 5449-5460 15 (1986))),
 - the *aceA* gene coding for isocitrate lyase (EC-No.: 4.1.3.1) (Matsuoka and McFadden; Journal of Bacteriology 170, 4528-4536 (1988) and Accession No.: AE000474), and
 - the *dgsA* gene coding for the regulator of the 20 phosphotransferase system (Hosono et al., Bioscience, Biotechnology and Biochemistry 59, 256-261 (1995) and Accession No.: AE000255)
- Furthermore for the production of L-amino acids, in particular L-threonine, it may be advantageous in addition 25 to the attenuation of the *fruR* gene also to switch off undesirable secondary reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).
- 30 The microorganisms produced according to the invention may be cultivated in a batch process (batch cultivation), in a

fed batch process (feed process) or in a repeated fed batch process (repetitive feed process). A summary of known cultivation methods is described in the textbook by Chmiel (*Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik* (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (*Bioreaktoren und periphere Einrichtungen* (Vieweg Verlag, Brunswick/Wiesbaden, 1994)).

The culture medium to be used must appropriately satisfy 10 the requirements of the respective strains. Descriptions of culture media of various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).

15 As carbon sources, sugars and carbohydrates such as for example glucose, sucrose, lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats such as for example soya bean oil, sunflower oil, groundnut oil and coconut oil, fatty acids such as for example 20 palmitic acid, stearic acid and linoleic acid, alcohols such as for example glycerol and ethanol, and organic acids such as for example acetic acid, may be used. These substances may be used individually or as a mixture.

As nitrogen source, organic nitrogen-containing compounds 25 such as peptones, yeast extract, meat extract, malt extract, maize steep liquor, soya bean flour and urea or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate may be used. The nitrogen sources may be 30 used individually or as a mixture.

As phosphorus source, phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts may be used. The culture medium must furthermore contain salts of metals,

- such as for example magnesium sulfate or iron sulfate, that are necessary for growth. Finally, essential growth promoters such as amino acids and vitamins may be used in addition to the aforementioned substances. Apart from 5 these, suitable precursors may be added to the culture medium. The aforementioned starting substances may be added to the culture in the form of a single batch or may be metered in in an appropriate manner during the cultivation.
- 10 In order to regulate the pH of the culture basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water, or acidic compounds such as phosphoric acid or sulfuric acid are used as appropriate. In order to control foam formation antifoaming agents such as for 15 example fatty acid polyglycol esters may be used. In order to maintain the stability of plasmids, suitable selectively acting substances, for example antibiotics, may be added to the medium. In order to maintain aerobic conditions, oxygen or oxygen-containing gas mixtures such as for 20 example air are fed into the culture. The temperature of the culture is normally 25°C to 45°C, and preferably 30°C to 40°C. Cultivation is continued until a maximum amount of L-amino acids (or L-threonine) has been formed. This target is normally achieved within 10 hours to 160 hours.
- 25 The L-amino acids may be analyzed by anion exchange chromatography followed by ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry, 30, (1958), 1190), or by reversed phase HPLC, as described by Lindroth et al. (Analytical Chemistry (1979) 51: 1167- 30 1174).

The process according to the invention can be used for the enzymatic production of L-amino acids, such as for example L-threonine, L-isoleucine, L-valine, L-methionine, L-homoserine and L-lysine, in particular L-threonine.

A pure culture of the Escherichia coli K-12 strain DH5 α /pMAK705 was filed as DSM 13720 on 8 September 2000 at the German Collection for Microorganisms and Cell Cultures (DSMZ, Brunswick, Germany) according to the Budapest Convention.

The present invention is described in more detail hereinafter with the aid of examples of implementation.

The isolation of plasmid DNA from Escherichia coli as well as all techniques for the restriction, ligation, Klenow treatment and alkaline phosphatase treatment are carried out according to Sambrook et al. (Molecular Cloning - A Laboratory Manual (1989) Cold Spring Harbor Laboratory Press). The transformation of Escherichia coli is, unless otherwise described, carried out according to Chung et al. (Proceedings of the National Academy of Sciences of the United States of America, USA (1989) 86: 2172-2175).

The incubation temperature in the production of strains and transformants is 37°C. In the gene exchange process according to Hamilton et al, temperatures of 30°C and 44°C are used.

Example 1

Construction of the deletion mutation of the fruR gene

Parts of the gene regions and parts of the 5'- and 3'- region of the fruR gene from Escherichia coli K12 lying upstream and downstream of the fruR gene are amplified using the polymerase chain reaction (PCR) as well as synthetic oligonucleotides. Starting from the nucleotide sequence of the fruR gene and sequences in E. coli K12 MG1655 DNA (SEQ ID No. 1, Accession Number AE000118) lying upstream and downstream, the following PCR primers are synthesized (MWG Biotech, Ebersberg, Germany):

fruR'5'-1: 5' - ATGAATCAGGCGCGTTATCC - 3' (SEQ ID No. 3)

fruR'5'-2: 5' - TTGTCGCTCACACGGTATTG - 3' (SEQ ID No. 4)

fruR'3'-1: 5' - AGCGTGTGCTGGAGATTGTC - 3' (SEQ ID No. 5)

fruR'3'-2: 5' - AGCCAGTCACAAGGCATACC - 3' (SEQ ID No. 6)

The chromosomal *E. coli* K12 MG1655 DNA used for the PCR is
5 isolated according to the manufacturer's instructions using
"Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany). A
ca. 750 bp large DNA fragment from the 5' region of the
fruR gene region (designated fruR1) and a ca. 650 bp large
DNA fragment from the 3' region of the fruR gene region
10 (designated as fruR2) may be amplified with the specific
primers under standard PCR conditions (Innis et al. (1990)
PCR Protocols. A Guide to Methods and Applications,
Academic Press) with the taq-DNA-polymerase (Gibco-BRL,
Eggenstein, Germany). The PCR products are ligated
15 according to the manufacturer's instructions in each case
with the vector pCR2.1TOPO (TOPO TA Cloning Kit,
Invitrogen, Groningen, Netherlands) and transformed in the
E. coli strain TOP10F'. The selection of plasmid-carrying
cells is carried out on LB agar to which 50 µg/ml of
20 ampicillin has been added. After the plasmid DNA isolation
the vector pCR2.1TOPOfruR2 is cleaved with the restriction
enzyme NotI and the supernatant 3'-ends are treated with
Klenow enzyme. After the restriction with the enzyme SpeI
the fruR2 fragment is separated in 0.8% agarose gel and
25 isolated using the QIAquick Gel Extraction Kit (QIAGEN,
Hilden, Germany). After the plasmid DNA isolation, the
vector pCR2.1TOPOfruR1 is cleaved with the enzymes EcoRV
and XbaI and ligated with the isolated fruR2 fragment. The
E. coli strain DH5 α is transformed with the ligation batch
30 and plasmid-carrying cells are selected on LB agar to which
50 µg/ml of ampicillin has been added. After the plasmid
DNA isolation those plasmids in which the mutagenic DNA
sequence illustrated in SEQ ID No. 7 is present in cloned
form are detected by control cleavage with the enzymes

HindIII, EcoRV and PvuI. One of the plasmids is designated pCR2.1TOPOΔfruR.

Example 2

Construction of the exchange vector pMAK705ΔfruR

- 5 The fruR allele described in Example 1 is isolated from the vector pCR2.1TOPOΔfruR after restriction with the enzyme EcoO109I, treatment of the supernatant 3'-ends with Klenow enzyme, restriction with the enzyme BamHI and separation in 0.8% agarose gel, and ligated with the plasmid pMAK705
- 10 (Hamilton et al. (1989) Journal of Bacteriology 171, 4617 - 4622) that has been digested with the enzymes HincII and BamHI. The ligation batch is transformed in DH5 α and plasmid-carrying cells are selected on LB agar to which 20 μ g/ml chloramphenicol had been added. Successful cloning
- 15 is detected after plasmid DNA isolation and cleavage with the enzymes HindIII, BamHI, EcoRV, ScaI and SpeI. The resultant exchange vector pMAK705ΔfruR (= pMAK705deltafruR) is shown in Fig. 1.

Example 3

- 20 Site-specific mutagenesis of the fruR gene in the E. coli strain MG442

The E. coli strain MG442 producing L-threonine is described in patent specification US-A- 4,278,765 and is filed as CMIM B-1628 at the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia).

For the exchange of the chromosomal fruR gene by the plasmid-coded deletion construct, MG442 is transformed with the plasmid pMAK705ΔfruR. The gene exchange is carried out by the selection process described by Hamilton et al. (1989) Journal of Bacteriology 171, 4617 - 4622) and is verified by standard PCR methods (Innis et al. (1990) PCR

Protocols. A guide to methods and applications, Academic Press) with the following oligonucleotide primers:

fruR'5'-1: 5' - ATGAATCAGGCGCGTTATCC - 3' (SEQ ID No. 3)

fruR'3'-2: 5' - AGCCAGTCACAAGGCATACC - 3' (SEQ ID No. 6)

- 5 After exchange has been carried out the form of the Δ fruR allele illustrated in SEQ ID No. 8 is present in MG442. The resultant strain is designated MG442 Δ fruR.

Example 4

Production of L-threonine using the strain MG442 Δ fruR

- 10 MG442 Δ fruR is cultivated on minimal medium having the following composition: 3.5 g/l Na₂HPO₄·2H₂O, 1.5 g/l KH₂PO₄, 1 g/l NH₄Cl, 0.1 g/l MgSO₄·7H₂O, 2 g/l glucose and 20 g/l agar. The formation of L-threonine is checked in batch cultures of 10 ml that are contained in 100 ml Erlenmeyer flasks. For this, 10 ml of preculture medium of the following composition: 2 g/l yeast extract, 10 g/l (NH₄)₂SO₄, 1 g/l KH₂PO₄, 0.5 g/l MgSO₄·7H₂O, 15 g/l CaCO₃, 20 g/l glucose are inoculated and incubated for 16 hours at 37°C and 180 rpm in an ESR incubator from Kühner AG (Birsfelden, Switzerland). 250 µl of this preculture are reinoculated in 10 ml of production medium (25 g/l (NH₄)₂SO₄, 2 g/l KH₂PO₄, 1 g/l MgSO₄·7H₂O, 0.03 g/l FeSO₄·7H₂O, 0.018 g/l MnSO₄·1H₂O, 30 g/l CaCO₃ and 20 g/l glucose) and incubated for 48 hours at 37°C. After incubation the optical density (OD) of the culture suspension is measured with an LP2W photometer from the Dr. Lange company (Dusseldorf, Germany) at a measurement wavelength of 660 nm.

- 30 The concentration of formed L-threonine is then determined in the sterile-filtered culture supernatant using an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany)

- BglII: restriction endonuclease from *Bacillus globigii*
- ClaI: restriction endonuclease from *Caryphanon latu*
- EcoRI: restriction endonuclease from *Escherichia col*
- 5 • EcoRV: restriction endonuclease from *Escherichia col*
- HindIII: restriction endonuclease from *Haemophilus influenzae*
- KpnI: restriction endonuclease from *Klebsiella pneumoniae*
- 10 • PstI: restriction endonuclease from *Providencia stuartii*
- PvuI: restriction endonuclease from *Proteus vulgari*
- SacI: restriction endonuclease from *Streptomyces achromogenes*
- 15 • SalI: restriction endonuclease from *Streptomyces albus*
- SmaI: restriction endonuclease from *Serratia marcescens*
- 20 • SphI: restriction endonuclease from *Streptomyces phaeochromogenes*
- SspI: restriction endonuclease from *Sphaerotilus species*
- XbaI: restriction endonuclease from *Xanthomonas badrii*
- 25 • XhoI: restriction endonuclease from *Xanthomonas holcicola*

What is Claimed is:

1. Process for the production of L-amino acids, in particular L-threonine, wherein the following steps are carried out:
 - 5 a) fermentation of the microorganisms of the family Enterobacteriaceae producing the desired L-amino acid, in which the fruR gene or nucleotide sequences coding therefor are attenuated, in particular are switched off,
 - 10 b) enrichment of the L-amino acid in the medium or in the cells of the microorganisms, and
 - 15 c) isolation of the L-amino acid, in which optionally constituents of the fermentation broth and/or the biomass in its entirety or portions thereof remain in the product.
- 20 2. Process according to claim 1, wherein microorganisms are used in which in addition further genes of the biosynthesis pathway of the desired L-amino acid are enhanced.
- 25 3. Process according to claim 1, wherein microorganisms are used in which the metabolic pathways that reduce the formation of the desired L-amino acid are at least partially switched off.
4. 4. Process according to claim 1, wherein the expression of the polynucleotide(s) that codes/code for the fruR gene is attenuated, in particular is switched off.
- 30 5. Process according to claim 1, wherein the regulatory and/or catalytic properties of the polypeptide (enzyme protein) for which the polynucleotide fruR codes are reduced.


6. Process according to claim 1, wherein for the production of L-amino acids microorganisms of the family Enterobacteriaceae are fermented in which at the same time one or more of the genes selected from
5 the following group is enhanced, in particular overexpressed:
- 6.1 the thrABC operon coding for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase,
- 10 6.2 the pyc gene coding for pyruvate carboxylase,
- 6.3 the pps gene coding for phosphoenol pyruvate synthase,
- 6.4 the ppc gene coding for phosphoenol pyruvate carboxylase,
- 15 6.5 the genes pntA and pntB coding for transhydrogenase,
- 6.6 the gene rhtB imparting homoserine resistance,
- 6.7 the mgo gene coding for malate:quinone oxidoreductase,
- 20 6.8 the gene rhtC imparting threonine resistance, and
- 6.9 the thrE gene coding for threonine export.
7. Process according to claim 1, wherein for the production of L-amino acids microorganisms of the family Enterobacteriaceae are fermented in which at
25 the same time one or more of the genes selected from the following group is attenuated, in particular switched off, or the expression is reduced:
- 7.1 the tdh gene coding for threonine dehydrogenase,

- 7.3 the gene product of the open reading frame (orf) *yjfa*,
- 7.4 the gene product of the open reading frame (orf) *ytfP*,
- 5 7.5 the *pckA* gene coding for phosphoenol pyruvate carboxykinase,
- 7.6 the *poxB* gene coding for pyruvate oxidase,
- 7.7 the *aceA* gene coding for isocitrate lyase,
- 7.8 the *dgsA* gene coding for the regulator of the phosphotransferase system.

10

1/1

Fig. 1:



SEQUENCE LISTING

5 <110> Degussa AG
 <120> Process for the production of L-amino acids using strains of the family Enterobacteriaceae containing an attenuated fruR gene
 10 <130> 020005 BT
 <160> 8
 15 <170> PatentIn version 3.1
 <210> 1
 <211> 2166
 <212> DNA
 20 <213> Escherichia coli
 <220>
 <221> CDS
 <222> (641)..(1645)
 25 <223> fruR gene
 <400> 1
 atgaatcagg cgcgttatcc cgcgtgattg gcctttttc ccagcgtggc tacaacattg 60
 aaaggctgac cgttgcgccca accgacgatc cgacattatc gcgtatgacc atccagaccg 120
 30 tgggcgatga aaaagtactt gagcagatcg aaaagcaatt acacaaactg gtcgatgtct 180
 tgccgcgttag tgagttgggg cagggcgcgc atgttgagcg ggaaatcatg ctggtaaaaa 240
 35 ttcaggccag cggttacggg cgtgacgaag tgaaacgtaa tacggaaata ttccgtggc 300
 aaattatcga tgcacacccc tcgccttata cgcgtcaatt agcaggcacc agcggtaagc 360
 40 ttatgcatt tttagcatcg attcgcgatg tggcgaaaat tgtggagggtt gctcgctctg 420
 gtgtggtcgg actttcgccgc ggcgataaaaa taatgcgttg agaatgatct caatgcgcaa 480
 45 ttacagccc aacatgtcac gttggcctt ttttgcgaaa tcagtggaa cctggaataaa 540
 aagcagttgc cgcagttaat tttctgcgt tagatgttaa tgaatttaac ccataccagt 600
 acaatggcta tggttttac attttacgca aggggcaatt gtg aaa ctg gat gaa 655
 Met Lys Leu Asp Glu
 50 1 5
 atc gct cgg ctg gcg gga gtg tcg cgg acc act gca agc tat gtt att 703
 Ile Ala Arg Leu Ala Gly Val Ser Arg Thr Thr Ala Ser Tyr Val Ile
 10 15 20
 55 aac ggc aaa gcg aag caa tac cgt gtg agc gac aaa acc gtt gaa aaa 751
 Asn Gly Lys Ala Lys Gln Tyr Arg Val Ser Asp Lys Thr Val Glu Lys
 25 30 35
 60 gtc atg gct gtg cgt gag cac aat tac cac ccg aac gcc gtg gca 799
 Val Met Ala Val Val Arg Glu His Asn Tyr His Pro Asn Ala Val Ala
 40 45 50
 65 gct ggg ctt cgt gct gga cgc aca cgt tct att ggt ctt gtg atc ccc 847
 Ala Gly Leu Arg Ala Gly Arg Thr Arg Ser Ile Gly Leu Val Ile Pro
 55 60 65

	gat ctg gag aac acc agc tat acc cgc atc gct aac tat ctt gaa cgc Asp Leu Glu Asn Thr Ser Tyr Thr Arg Ile Ala Asn Tyr Leu Glu Arg 70 75 80 85	895
5	cag gcg cgg caa cgg ggt tat caa ctg ctg att gcc tgc tca gaa gat Gln Ala Arg Gln Arg Gly Tyr Gln Leu Leu Ile Ala Cys Ser Glu Asp 90 95 100	943
10	cag cca gac aac gaa atg cgg tgc att gag cac ctt tta cag cgt cag Gln Pro Asp Asn Glu Met Arg Cys Ile Glu His Leu Leu Gln Arg Gln 105 110 115	991
15	gtt gat gcc att att gtt tcg acg tcg ttg cct cct gag cat cct ttt Val Asp Ala Ile Ile Val Ser Thr Ser Leu Pro Pro Glu His Pro Phe 120 125 130	1039
20	tat caa cgc tgg gct aac gac ccg ttc ccg att gtc gcg ctg gac cgc Tyr Gln Arg Trp Ala Asn Asp Pro Phe Pro Ile Val Ala Leu Asp Arg 135 140 145	1087
25	gcc ctc gat cgt gaa cac ttc acc agc gtg gtt ggt gcc gat cag gat Ala Leu Asp Arg Glu His Phe Thr Ser Val Val Gly Ala Asp Gln Asp 150 155 160 165	1135
30	gat gcc gaa atg ctg gcg gaa gag tta cgt aag ttt ccc gcc gag acg Asp Ala Glu Met Leu Ala Glu Glu Leu Arg Lys Phe Pro Ala Glu Thr 170 175 180	1183
35	gtg ctt tat ctt ggt gcg cta ccg gag ctt tct gtc agc ttc ctg cgt Val Leu Tyr Leu Gly Ala Leu Pro Glu Leu Ser Val Ser Phe Leu Arg 185 190 195	1231
40	gaa caa ggt ttc cgt act gcc tgg aaa gat gat ccg cgc gaa gtg cat Glu Gln Gly Phe Arg Thr Ala Trp Lys Asp Asp Pro Arg Glu Val His 200 205 210	1279
45	ttc ctg tat gcc aac agc tat gag cgg gag gcg gct gcc cag tta ttc Phe Leu Tyr Ala Asn Ser Tyr Glu Arg Glu Ala Ala Gln Leu Phe 215 220 225	1327
50	gaa aaa tgg ctg gaa acg cat ccg atg ccg cag gcg ctg ttc aca acg Glu Lys Trp Leu Glu Thr His Pro Met Pro Gln Ala Leu Phe Thr Thr 230 235 240 245	1375
55	tcg ttt gcg ttg ttg caa gga gtg atg gat gtc agc ctg cgt cgc gac Ser Phe Ala Leu Leu Gln Gly Val Met Asp Val Thr Leu Arg Arg Asp 250 255 260	1423
60	ggc aaa ctg cct tct gac ctg gca att gcc acc ttt ggc gat aac gaa Gly Lys Leu Pro Ser Asp Leu Ala Ile Ala Thr Phe Gly Asp Asn Glu 265 270 275	1471
65	ctg ctc gac ttc tta cag tgt ccg gtg ctg gca gtg gct caa cgt cac Leu Leu Asp Phe Leu Gln Cys Pro Val Leu Ala Val Ala Gln Arg His 280 285 290	1519
70	cgc gat gtc gca gag cgt gtg ctg gag att gtc ctg gca agc ctg gac Arg Asp Val Ala Glu Arg Val Leu Glu Ile Val Leu Ala Ser Leu Asp 295 300 305	1567
75	gaa ccg cgt aag cca aaa cct ggt tta acg cgc att aaa cgt aat ctc Glu Pro Arg Lys Pro Lys Pro Gly Leu Thr Arg Ile Lys Arg Asn Leu 310 315 320 325	1615

	tat cgc cgc ggc gtg ctc agc cgt agc taa gcccgcgaaca aaaatacgcg Tyr Arg Arg Gly Val Leu Ser Arg Ser 330	1665
5	ccaggtgaat ttccctctgg cgcgtagagt acgggactgg acatcaatat gcttaaagta aataagacta ttccctgacta ttattgataa atgcctttaa acccgcccgt taattaactc 10	1725
	accagctgaa attcacaata attaagtgat atcgacagcg cggtttgca ttatttgtt 15	1785
10	acatgcggcg atgaattgcc gatttaacaa acactttct ttgctttgc gcaaaccgc tggcatcaag cgcccacacag acgtaacaag gactgttaac cgggaaagat atgtcctaaa 15	1845
	atgcccctcg cgtcgcaaac tgacacttta tatttgctgt ggaaaatagt gagtcattt 20	1905
15	aaaacggtga tgacgatgag ggatttttc ttacagctat tcataacgtt aatttgcttc gcacgttgga cgtaaaataa acaacgctga tattagccgt aaacatcggg tttttacct 20	1965
	cggtatgcct tgtgactggc t <210> 2 <211> 334 25 <212> PRT <213> Escherichia coli <400> 2	2025
30	Met Lys Leu Asp Glu Ile Ala Arg Leu Ala Gly Val Ser Arg Thr Thr 1 5 10 15 Ala Ser Tyr Val Ile Asn Gly Lys Ala Lys Gln Tyr Arg Val Ser Asp 20 25 30	2085
35	Lys Thr Val Glu Lys Val Met Ala Val Val Arg Glu His Asn Tyr His 35 40 45	2145
	Pro Asn Ala Val Ala Ala Gly Leu Arg Ala Gly Arg Thr Arg Ser Ile 50 55 60	2166
40	Gly Leu Val Ile Pro Asp Leu Glu Asn Thr Ser Tyr Thr Arg Ile Ala 65 70 75 80	
	Asn Tyr Leu Glu Arg Gln Ala Arg Gln Arg Gly Tyr Gln Leu Leu Ile 45 85 90 95	
	Ala Cys Ser Glu Asp Gln Pro Asp Asn Glu Met Arg Cys Ile Glu His 100 105 110	
50	Leu Leu Gln Arg Gln Val Asp Ala Ile Ile Val Ser Thr Ser Leu Pro 115 120 125	
	Pro Glu His Pro Phe Tyr Gln Arg Trp Ala Asn Asp Pro Phe Pro Ile 130 135 140	
55	Val Ala Leu Asp Arg Ala Leu Asp Arg Glu His Phe Thr Ser Val Val 145 150 155 160	
	Gly Ala Asp Gln Asp Asp Ala Glu Met Leu Ala Glu Glu Leu Arg Lys 60 165 170 175	
	Phe Pro Ala Glu Thr Val Leu Tyr Leu Gly Ala Leu Pro Glu Leu Ser 180 185 190	
65	Val Ser Phe Ala - 17 W. GLN GLY Ala Arg Thr Ala Arg Lys Asp Asp	

	195	200	205	
	Pro Arg Glu Val His Phe Leu Tyr Ala Asn Ser Tyr Glu Arg Glu Ala			
	210	215	220	
5	Ala Ala Gln Leu Phe Glu Lys Trp Leu Glu Thr His Pro Met Pro Gln			
	225	230	235	240
10	Ala Leu Phe Thr Thr Ser Phe Ala Leu Leu Gln Gly Val Met Asp Val			
	245	250	255	
	Thr Leu Arg Arg Asp Gly Lys Leu Pro Ser Asp Leu Ala Ile Ala Thr			
	260	265	270	
15	Phe Gly Asp Asn Glu Leu Leu Asp Phe Leu Gln Cys Pro Val Leu Ala			
	275	280	285	
	Val Ala Gln Arg His Arg Asp Val Ala Glu Arg Val Leu Glu Ile Val			
	290	295	300	
20	Leu Ala Ser Leu Asp Glu Pro Arg Lys Pro Lys Pro Gly Leu Thr Arg			
	305	310	315	320
	Ile Lys Arg Asn Leu Tyr Arg Arg Gly Val Leu Ser Arg Ser			
25	325	330		
	<210> 3			
	<211> 20			
	<212> DNA			
30	<213> Artificial sequence			
	<220>			
	<221> Primer			
	<222> (1)..(20)			
35	<223> fruR'5'-1			
	<400> 3			
	atgaatcagg cgcgttatcc			20
40	<210> 4			
	<211> 20			
	<212> DNA			
	<213> Artificial sequence			
45	<220>			
	<221> Primer			
	<222> (1)..(20)			
	<223> fruR'5'-2			
50	<400> 4			
	ttgtcgctca cacggatttg			20
	<210> 5			
	<211> 20			
55	<212> DNA			
	<213> Artificial sequence			
	<220>			
	<221> Primer			
60	<222> (1)..(20)			
	<223> fruR'3'-1			
	<400> 5			
	agcgtgtgct ggagattgtc			20
65				

<210> 6
<211> 20
<212> DNA
<213> Artificial sequence
5
<220>
<221> Primer
<222> (1)..(20)
<223> fruR'3'-2
10
<400> 6
agccagtac aaggcatacc 20

<210> 7
15 <211> 1512
<212> DNA
<213> Escherichia coli

<220>
20 <221> misc_feature
<222> (1)..(1512)
<223> Mutagenic DNA

<220>
25 <221> misc_feature
<222> (1)..(42)
<223> Technical DNA/ remainder polylinker sequence

<220>
30 <221> misc_feature
<222> (43)..(780)
<223> Part of the upstream-lying region and part of the 5'-region of the
fruR gene

35 <220>
<221> misc_feature
<222> (781)..(837)
<223> Technical DNA/ remainder polylinker sequence

40 <220>
<221> misc_feature
<222> (838)..(1471)
<223> Part of the 3'-region of the fruR gene and part of the downstream-
lying region
45
<220>
<221> misc_feature
<222> (1472)..(1512)
<223> Technical DNA/ remainder polylinker sequence
50
<400> 7
gatccactag taacggccgc cagtgtgctg gaattcgccc ttatgaatca ggccgcgttat 60
ccccgcgtat tggccctttt tcccagcgtg gctacaacat tgaaaagcctg accgttgcgc 120
55 caaccgacga tccgacatta tcgcgtatga ccatccagac cgtgggcgtat gaaaaagtac 180
ttgagcagat cgaaaagcaa ttacacaaac tggtcgatgt cttgcgcgtg agtgagttgg 240
60 ggcagggcgc gcatgtttag cggaaatca tgctggtaa aattcaggcc agcggttacg 300
ggcgtacga agtgaaacgt aatacggaaa tattccgtgg gcaaattatc gatgtcacac 360
65 cctcgcttta taccgttcaa ttagcaggca ccagcggtaa gcttgatgca ttttagcat 420

cgattcgcga tgtggcgaaa attgtggagg ttgctcgctc tgggtggtc ggactttcgc 480
 gcggcgataa aataatgcgt tgagaatgat ctcaatgcgc aatttacagc ccaacatgtc 540
 5 acgttggct tttttgcga aatcagtggg aacctggaat aaaagcagtt gccgcagttta 600
 attttctgcg ctttagatgtt aatgaattta acccataccca gtacaatggc tatggtttt 660
 10 acatttacg caagggcaa ttgtgaaact gnatgaaatc gctcgctgg cgggagtgtc 720
 gcggaccact gcaagctatg ttattaacgg caaagcgaag caataccgtg tgagcgacaa 780
 aagggcgaat tctgcagatg gccgccagtg tgatggatat ctgcagaatt cgcccttagc 840
 15 gtgtgctgga gattgtcctg gcaagcctgg acgaaccgcg taagccaaaa cctggttaa 900
 cgcgcatcaa acgtaatctc tatcgccgcg gcgtgcttagt ccgtagctaa gcccgcgaaca 960
 20 aaaatacgcg ccaggtgaat ttccctctgg cgctgtagagt acgggactgg acatcaatat 1020
 gcttaaagta aataagacta ttccctgacta ttattgataa atgctttaa acccgccccgt 1080
 taattaactc accagctgaa attcacaata attaagtgtat atcgacagcg cgaaaaatgtc 1140
 25 ttattttgtt acatgcggcg atgaattgcc gatttaacaa acactttct ttgctttgc 1200
 gcaaaaccgcg tggcatcaag cgccacacag acgtaacaag gactgttaac cggggaaagat 1260
 30 atgtcctaaa atgcccgtcg cgctgcaaac tgacacttta tatttgctgt ggaaaaatagt 1320
 gagtcattt aaaacggtga tgacgatgag ggatttttc ttacagctat tcataacgtt 1380
 aatttgcttc gcacgttggc cgtaaaataa acaacgctga tattagccgt aaacatcgccg 1440
 35 ttttttacct cggtatgcct tgtgactggc taagggcgaa ttccagcaca ctggcggccg 1500
 ttactagagg gc 1512

<210> 8
 40 <211> 268
 <212> DNA
 <213> Escherichia coli

<220>
 45 <221> misc_feature
 <222> (1)..(268)
 <223> Mutagenic DNA

<220>
 50 <221> misc_feature
 <222> (1)..(3)
 <223> Start codon of the delta fruR allele

<220>
 55 <221> misc_feature
 <222> (1)..(98)
 <223> 5'-region of the delta fruR allele

<220>
 60 <221> misc_feature
 <222> (99)..(155)
 <223> Technical DNA/ remainder polylinker sequence

<220>
 65 <221> misc_feature

<222> (156)..(265)
<223> 3'-region of the delta fruR allele

5 <220>
<221> misc_feature
<222> (266)..(268)
<223> Stop codon of the delta fruR allele

10 <400> 8
gtgaaaactgg atgaaatcg tcggctggcg ggagtgtcgc ggaccactgc aagctatgtt 60
attaacggca aagcgaagca ataccgtgtg agcgacaaaa gggcgaattc tgcagatggc 120
15 cggcagtgtg atggatatct gcagaattcg cccttagcgt gtgctggaga ttgtccctggc 180
aaggctggac gaaccgcgta agccaaaacc tggtttaacg cgcatthaac gtaatctcta 240
tcggccggc gtgctcagcc gtagctaa 268

20

PCT

Original (for SUBMISSION) - printed on 05.03.2002 09:02:18 AM

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	PCT-EASY Version 2.92 (updated 01.01.2002)
0-2	International Application No.	
0-3	Applicant's or agent's file reference	020005 BT
1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	13
1-2	line	1-5
1-3	Identification of Deposit	
1-3-1	Name of depositary institution	DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
1-3-2	Address of depositary institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
1-3-3	Date of deposit	08 September 2000 (08.09.2000)
1-3-4	Accession Number	DSMZ 13720
1-4	Additional Indications	NONE
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the International application: (yes or no)	Yes
0-4-1	Authorized officer	 C.A.J.A. PASCHE

FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the International Bureau on:	
0-5-1	Authorized officer	

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Degussa-Hüls AG
Kantstr. 2
33790 Halle

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITORY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: DH5 α /pMAK705	Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY: DSM 13720
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
<p>The microorganism identified under I. above was accompanied by:</p> <p><input checked="" type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation</p> <p>(Mark with a cross where applicable).</p>	
III. RECEIPT AND ACCEPTANCE	
<p>This International Depository Authority accepts the microorganism identified under I. above, which was received by it on 2000-09-08 (Date of the original deposit)¹.</p>	
IV. RECEIPT OF REQUEST FOR CONVERSION	
<p>The microorganism identified under I. above was received by this International Depository Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).</p>	
V. INTERNATIONAL DEPOSITORY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depository Authority or of authorized official(s): <i>Dagmar Frize</i> Date: 2000-09-12

¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depository authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Degussa-Hüls AG
Kantstr. 2
33790 Halle

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITORY AUTHORITY
Identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: Degussa-Hüls AG Kantstr. 2 Address: 33790 Halle	Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY: DSM 13720 Date of the deposit or the transfer ¹ : 2000-09-08
III. VIABILITY STATEMENT	
<p>The viability of the microorganism identified under II above was tested on 2000-09-08². On that date, the said microorganism was</p> <p><input checked="" type="checkbox"/>³ viable <input type="checkbox"/> no longer viable</p>	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED ⁴	
V. INTERNATIONAL DEPOSITORY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depository Authority or of authorized official(s): <i>Dagmar Trin</i> Date: 2000-09-12

¹ Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

² In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

³ Mark with a cross the applicable box.

⁴ Fill in if the information has been requested and if the results of the test were negative.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081698 A3

(51) International Patent Classification⁷: C12P 13/08,
13/04 // (C12P 13/08, C12R 1:19)

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.

(22) International Filing Date: 6 March 2002 (06.03.2002)

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(25) Filing Language: English

Published:

(26) Publication Language: English

- with international search report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

(30) Priority Data:
101 16 518.8 3 April 2001 (03.04.2001) DE

(88) Date of publication of the international search report:
30 October 2003


(71) Applicant: DEGUSSA AG [DE/DE]; Bennigsenplatz 1,
40474 Düsseldorf (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors: RIEPING, Mechthild; Mönkebergstrasse 1,
33619 Bielefeld (DE). HERMANN, Thomas; Zirkonstrasse 8, 33739 Bielefeld (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

(54) Title: PROCESS FOR THE PRODUCTION OF L-AMINO ACIDS USING STRAINS OF THE FAMILY ENTEROBACTERIACEAE THAT CONTAIN AN ATTENUATED FRUR GENE



(57) Abstract: The invention relates to a process for the production of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of the microorganisms of the family Enterobacteriaceae producing the desired L-amino acid, in which the fruR gene or nucleotide sequences coding therefor are attenuated, in particular are switched off, b) enrichment of the L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid.

02/081698 A3

INTERNATIONAL SEARCH REPORT

Intern	al Application No
PCT/EP 02/02420	

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C12P13/08 C12P13/04 // (C12P13/08, C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C12P C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99 53035 A (ALTMAN ELLIOT ;GOKARN RAVI R (US); EITEMAN MARK A (US); UNIV GEORG) 21 October 1999 (1999-10-21) page 5, line 20-24 examples 4,7,9,10 claims 41,49 figures 1,4	1-7
Y	RAMSEIER T M: "Control and the control of carbon flux via metabolic pathways." RESEARCH IN MICROBIOLOGY, vol. 147, no. 6-7, July 1996 (1996-07), pages 489-493, XP002241023 ISSN: 0923-2508 the whole document figure 1	1-7

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search

Date of mailing of the International search report

20 May 2003

02/06/2003

Name and mailing address of the ISA

Authorized officer

European Patent Office, P.O. Box 5618 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel: (+31-70) 346-2140, Fax: +31 70 346 2016

Mr. J. De Kort, P.

INTERNATIONAL SEARCH REPORT

Interr - AI Application No
PCT/EP 02/02420

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JAHREIS K ET AL.: "Nucleotide sequence of the ilvH-frur gene region of Escherichia coli K12 and Salmonella typhimurium LT2" MOLECULAR AND GENERAL GENETICS, vol. 226, no. 1/2, April 1991 (1991-04), pages 332-336, XP002937889 ISSN: 0026-8925 cited in the application the whole document	1-7
A	MICHAL G: "Biochemical pathways: an atlas of biochemistry and molecular biology" 1999 , JOHN WILEY & SONS INC. AND SPEKTRUM AKADEMISCHER VERLAG , NEW YORK - HEIDELBERG XP002240819 ISBN: 0-471-33130-9 figures 3.8-1 and 3.8-2 figures 4.2-1, 4.5-1 and 4.5-2 paragraph "4.5.3!"	1-7
A	KRAEMER R: "Genetic and physiological approaches for the production of amino acids" JOURNAL OF BIOTECHNOLOGY, vol. 45, no. 1, 1996, pages 1-21, XP002178648 ISSN: 0168-1656 the whole document	1-7
A	US 4 278 765 A (DEBABOV VLADIMIR G ET AL) 14 July 1981 (1981-07-14) cited in the application the whole document	1-7
A	EP 0 643 135 A (AJINOMOTO KK) 15 March 1995 (1995-03-15) the whole document	1-7
A	EP 0 237 819 A (KYOWA HAKKO KOGYO KK) 23 September 1987 (1987-09-23) the whole document	1-7
A	DATABASE WPI Section Ch, Week 199148 Derwent Publications Ltd., London, GB; Class B05, AN 1991-351136 XP002241222 & JP 03 236786 A (KYOWA HAKKO KOGYO KK), 22 October 1991 (1991-10-22) abstract	1-7
	-/-	

INTERNATIONAL SEARCH REPORT

Intern - si Application No
PCT/EP 02/02420

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 952 221 A (AJINOMOTO KK) 27 October 1999 (1999-10-27) page 2, line 24 -page 3, line 2 page 6, line 42 -page 7, line 6 claim 1 ---	1-7
A	EP 0 955 368 A (AJINOMOTO KK) 10 November 1999 (1999-11-10) page 2, line 22-56 page 6, line 9-31 claim 6 ---	1-7
A	JETTEN M S M ET AL.: "Recent advances in the physiology and genetics of amino acid-producing bacteria." CRC CRITICAL REVIEWS IN BIOTECHNOLOGY, vol. 15, no. 1, 1995, pages 73-103, XP000613291 ISSN: 0738-8551 figure 1 page 90, left-hand column, line 1 -page 92, left-hand column, line 17 ---	1-7
A	SAWERS G: "The anaerobic degradation of L-serine and L-threonine in enterobacteria: networks of pathways and regulatory signals" ARCHIVES OF MICROBIOLOGY, vol. 171, no. 1, 1998, pages 1-5, XP002953871 ISSN: 0302-8933 the whole document ---	1-7
E	WO 02 081721 A (DEGUSSA) 17 October 2002 (2002-10-17) the whole document page 9, line 24 -page 10, line 25 claim 7 ---	1-7
E	WO 02 081722 A (DEGUSSA) 17 October 2002 (2002-10-17) the whole document page 9, line 21 -page 10, line 22 claim 7 ---	1-7

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No
PCT/EP 02/02420

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9953035	A	21-10-1999	AU BR CA EP JP WO US US	3555999 A 9909615 A 2325598 A1 1073722 A1 2002511250 T 9953035 A1 2003087381 A1 6455284 B1	01-11-1999 12-12-2000 21-10-1999 07-02-2001 16-04-2002 21-10-1999 08-05-2003 24-09-2002
US 4278765	A	14-07-1981	SU HU	875663 A1 190999 B	15-09-1982 28-12-1986
EP 0643135	A	15-03-1995	AT CZ DE DE DK EP JP SK US EP ES WO RU	203769 T 9401658 A3 69330518 D1 69330518 T2 643135 T3 0643135 A1 3331472 B2 81994 A3 5661012 A 1020526 A2 2158867 T3 9411517 A1 2113484 C1	15-08-2001 15-12-1994 06-09-2001 08-05-2002 15-10-2001 15-03-1995 07-10-2002 10-05-1995 26-08-1997 19-07-2000 16-09-2001 26-05-1994 20-06-1998
EP 0237819	A	23-09-1987	DE DE EP JP JP KR US	3788583 D1 3788583 T2 0237819 A2 2574786 B2 63273487 A 9108634 B1 5017483 A	10-02-1994 19-05-1994 23-09-1987 22-01-1997 10-11-1988 19-10-1991 21-05-1991
JP 3236786	A	22-10-1991	JP	2877414 B2	31-03-1999
EP 0952221	A	27-10-1999	AU AU BR CN EP JP PL US US	756507 B2 2122399 A 9901173 A 1233660 A 0952221 A2 2000189169 A 332072 A1 6331419 B1 2001019836 A1	16-01-2003 30-09-1999 28-03-2000 03-11-1999 27-10-1999 11-07-2000 27-09-1999 18-12-2001 06-09-2001
EP 0955368	A	10-11-1999	AU AU BR CN EP JP PL RU US US	746542 B2 2122499 A 9901174 A 1233661 A 0955368 A2 2000106869 A 332071 A1 2188236 C2 6197559 B1 2002004231 A1	02-05-2002 30-09-1999 28-03-2000 03-11-1999 10-11-1999 18-04-2000 27-09-1999 27-08-2002 06-03-2001 10-01-2002
WO 02081721	A	17-10-2002	DE	10116518 A1	17-10-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.

PCT/EP 02/02420

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 02081721	A		WO 02081721 A2	17-10-2002
			WO 02081698 A2	17-10-2002
			WO 02081722 A2	17-10-2002
			US 2003054503 A1	20-03-2003
			US 2003059903 A1	27-03-2003
WO 02081722	A	17-10-2002	DE 10116518 A1	17-10-2002
			WO 02081721 A2	17-10-2002
			WO 02081698 A2	17-10-2002
			WO 02081722 A2	17-10-2002
			US 2003054503 A1	20-03-2003
			US 2003059903 A1	27-03-2003